Vasculogenic Erectile Dysfunction:
We don’t ask, they don’t talk

Roxana Mehran, MD, FACC, FAHA, FESC, MSCAI
Mount Sinai Professor Of Cardiovascular Clinical Research and Outcomes,
Professor of Medicine (Cardiology), and Population Health Science and Policy,
Director of Interventional Cardiovascular Research and Clinical Trials,
Icahn School of Medicine at Mount Sinai, New York, NY, USA

@DrRoxMehran
Roxana.Mehran@mountsinai.org
## Disclosures

<table>
<thead>
<tr>
<th>Affiliation/Financial Relationship</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Consultant/Advisory/Speaking Engagements</strong></td>
<td>Abbott Laboratories (to institution), Abiomed (spouse), Boston Scientific, Idorsia Pharmaceuticals Ltd. (no fee), Janssen, Medscape/WebMD, Medtelligence (Janssen Scientific Affairs), Roivant Sciences Inc, Sanofi, Siemens Medical Solutions, Regeneron Pharmaceuticals (no fee), Spectranetics/Philips/Volcano Corp (to institution), The Medicines Company (spouse)</td>
</tr>
<tr>
<td><strong>Research Funding to Institution</strong></td>
<td>Abbott Laboratories, Abiomed, AstraZeneca, Bayer, Beth Israel Deaconess, BMS, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Medtronic, Novartis, OrbusNeich</td>
</tr>
<tr>
<td><strong>Scientific Advisory Board</strong></td>
<td>Bristol-Myers Squibb (to institute), Medtelligence (Janssen Scientific Affairs), Merck (spouse)</td>
</tr>
<tr>
<td><strong>Equity, &lt;1%</strong></td>
<td>Claret Medical, Elixir Medical</td>
</tr>
<tr>
<td><strong>DSMB membership paid to the institution</strong></td>
<td>Watermark Research Partners</td>
</tr>
<tr>
<td><strong>Associate Editor</strong></td>
<td>ACC, AMA</td>
</tr>
</tbody>
</table>
Erectile Dysfunction

ED negatively impacts quality of life:
Self esteem, depression, relationships
What is Erectile Dysfunction?

Erectile dysfunction (ED) is defined as the recurrent inability to achieve and maintain an erection satisfactory for sexual intercourse.
Clinical Relevance of ED

- Erectile dysfunction is a common medical disorder that primarily affects men older than 40 years of age and it is becoming a major health problem for the increasingly healthy aging population.

- The worldwide prevalence of ED is estimated to increase from 152 million cases in 1995 to 322 million by the year 2025 (1)

- A large number of pts (46%) with ischemic heart disease are suffering from ED (2)

---

(1) Aytal I., McElinay J., Krane R. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50–56.

Risk Factors of ED

- Vascular (atherosclerotic, venous leakage)
- Diabetes mellitus
- Medication (beta-blockers, cimetidine)
- Pelvic surgery, radiation, trauma
- Neurological causes
- Endocrine problems
Common Questions and Myths surrounding ED

- Nothing can be done
- This is expected at my age, isn’t it?
- Is this a psychologic issue?
Normal Erectile Function

- *Intact nervous system network*
- *Sufficient blood flow*
- *Intact/healthy cavernosal tissue*
- *Normal venous drainage*
Link Between ED and CVD

- **Risk Factors**
  - Age, DM, HTN
  - Alcohol, tobacco

- **Up to 46% of men with CAD and >85% with CHF have ED**

- **Of men with ED: 75% with CAD have problem achieving erection and 65% maintaining it**

- **ED predates the onset of symptomatic CVD by ~ 3 years in large numbers of cases**

- **ED increases the risk of CV events by 44%, 62% for MI and 25% for overall mortality**

---

How Should You Approach Patients with a Vasculogenic Erectile Dysfunction?

Session Agenda:

- What current European Guidelines suggest for the Treatment of ED (Ferdinando Fusco)
- How Cardiologist should approach the patients with ED (Giuseppe Sangiorgi)
- Treatment of erectile dysfunction: from pills to balloons and stents (Nicolas Diehm)
- Clinical Cases (Giuseppe Sangiorgi)
- Clinical Cases (Nicolas Diehm)
- Discussion
Thank You!

@Drroxmehran
Roxana.Mehran@mountsinai.org